<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04498910</url>
  </required_header>
  <id_info>
    <org_study_id>17124</org_study_id>
    <secondary_id>J1H-MC-LAJB</secondary_id>
    <nct_id>NCT04498910</nct_id>
  </id_info>
  <brief_title>A Study of LY3451838 in Participants With Migraine</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY3451838 in Adults With Treatment-Resistant Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The reason for this study is to see if the study drug LY3451838 is safe and effective in&#xD;
      participants who have migraine that have not responded to other preventive treatments.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2020</start_date>
  <completion_date type="Anticipated">November 17, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 17, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in the Number of Monthly Migraine Headache Days</measure>
    <time_frame>Baseline, Month 1</time_frame>
    <description>Change from Baseline in the Number of Monthly Migraine Headache Days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Number of Monthly Headache Days</measure>
    <time_frame>Baseline, Month 1</time_frame>
    <description>Change from Baseline in the Number of Monthly Headache Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with ≥50% Reduction from Baseline in Monthly Migraine Headache Days</measure>
    <time_frame>Month 1</time_frame>
    <description>Percentage of Participants with ≥50% Reduction from Baseline in Monthly Migraine Headache Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs)</measure>
    <time_frame>Baseline up to 5 Months</time_frame>
    <description>Number of Participants with One or More SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3451838</measure>
    <time_frame>Baseline through Month 1</time_frame>
    <description>PK: AUC of LY3451838</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Maximum Observed Drug Concentration (Cmax) of LY3451838</measure>
    <time_frame>Baseline through Month 1</time_frame>
    <description>PK: Cmax of LY3451838</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>LY3451838</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3451838 given intravenously (IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3451838</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>LY3451838</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must have a diagnosis of migraine with a history of migraine headaches of at least 1&#xD;
             year prior, and migraine onset prior to age 50.&#xD;
&#xD;
          -  Have completed at least 80% of required daily diary entries during the start of the&#xD;
             study.&#xD;
&#xD;
          -  Have documentation of previous failure of 2 to 4 standard-of-care migraine preventive&#xD;
             medication categories in the past 10 years.&#xD;
&#xD;
          -  Women of child-bearing potential must test negative for pregnancy as indicated by a&#xD;
             negative serum pregnancy test and negative urine pregnancy test.&#xD;
&#xD;
          -  Women of child-bearing potential who are abstinent or in a same sex relationship must&#xD;
             agree to either remain abstinent or to avoid sexual relationships with males.&#xD;
&#xD;
          -  Women of child-bearing potential who are not abstinent, must agree to use one highly&#xD;
             effective method of contraception, or a combination of two effective methods of&#xD;
             contraception during the study, as well as 5 months following.&#xD;
&#xD;
          -  Women not of childbearing potential may participate and include those who are: A.&#xD;
             Infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy or tubal&#xD;
             ligation) or congenital anomaly; or B. Post-menopausal - defined as either:&#xD;
&#xD;
               -  i. a woman at least 40 years of age with an intact uterus, not on hormone&#xD;
                  therapy, who has cessation of menses for at least 1 year without an alternative&#xD;
                  medical cause, and a follicle-stimulating hormone greater than (&gt;) 40&#xD;
                  multi-international units per milliliter (mIU/mL); or&#xD;
&#xD;
               -  ii. a woman 55 or older not on hormone therapy, who has had at least 12 months of&#xD;
                  spontaneous amenorrhea; or&#xD;
&#xD;
               -  iii. a woman at least 55 years of age with a diagnosis of menopause prior to&#xD;
                  starting hormone replacement therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are currently enrolled in any other clinical study or any other type of medical&#xD;
             research judged not to be compatible with this study.&#xD;
&#xD;
          -  Have participated, within the last 30 days or 5-half-lives (whichever is longer), in a&#xD;
             clinical study involving any investigational product. If the half-life of the&#xD;
             investigational product is unknown, 6 months should have passed prior.&#xD;
&#xD;
          -  Known hypersensitivity or intolerance to monoclonal antibodies or other therapeutic&#xD;
             proteins, or to common antihistamines, epinephrine, methyl prednisone or other&#xD;
             systemic corticosteroids.&#xD;
&#xD;
          -  Are currently receiving medication or other treatment for prevention of migraine&#xD;
             headaches. Participants must have discontinued such medications or treatments at least&#xD;
             2 weeks prior. Botulinum toxin A or B that has been administered in the head or neck&#xD;
             area use must be discontinued at least 3 months prior. Nerve blocks or device use&#xD;
             (such as transcranial magnetic stimulation or electrical nerve stimulation) in the&#xD;
             head or neck area for migraine treatment must be discontinued at least 30 days prior.&#xD;
             Anti-calcitonin gene-related peptide (CGRP) antibodies must be discontinued at least 5&#xD;
             half-lives prior.&#xD;
&#xD;
          -  Have previously failed more than 4 migraine preventive medication categories in the&#xD;
             past 10 years due to inadequate efficacy (that is, maximum tolerated dose for at least&#xD;
             2 months) and/or safety / tolerability reasons.&#xD;
&#xD;
          -  History of cluster headache or migraine subtypes including hemiplegic (sporadic or&#xD;
             familial) migraine, ophthalmoplegic migraine, retinal migraine, typical aura without&#xD;
             headache, complications of migraine and migraine with brainstem aura (basilar-type&#xD;
             migraine).&#xD;
&#xD;
          -  In the 3 months prior, have other types of headache besides migraine, tension type&#xD;
             headache, or medication overuse headache (MOH). (In other words, participants can have&#xD;
             migraine, tension type headache, or MOH in the 3 months prior, but they cannot have&#xD;
             other types of headache in that time).&#xD;
&#xD;
          -  History of head or neck injury within last 6 months.&#xD;
&#xD;
          -  History of traumatic cervical or head injury associated with significant change in the&#xD;
             quality or frequency of headaches.&#xD;
&#xD;
          -  Have reading of electrocardiogram (ECG) showing abnormalities considered incompatible&#xD;
             with the study.&#xD;
&#xD;
          -  Any liver tests outside the normal range.&#xD;
&#xD;
          -  Evidence of significant active or unstable psychiatric disease.&#xD;
&#xD;
          -  Women who are pregnant or nursing.&#xD;
&#xD;
          -  Participants who have used opioids or barbiturate-containing analgesic &gt;4 days per&#xD;
             month for the treatment of pain in each of the past 3 months.&#xD;
&#xD;
          -  History of drug or alcohol abuse/dependence within 1 year.&#xD;
&#xD;
          -  Have a positive urine drug screen for illicit drugs.&#xD;
&#xD;
          -  Are unwilling or unable to comply with the use of data collection devices.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>21st Century Neurology</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004-0000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>602-265-6500</phone>
    </contact>
    <investigator>
      <last_name>Stephen Flitman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New England Institute for Clinical Research</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>203-914-1900</phone>
    </contact>
    <investigator>
      <last_name>Peter J McAllister</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>352-629-5800</phone>
    </contact>
    <investigator>
      <last_name>Anette V. Nieves</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emerald Coast Center for Neurological Disorders</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>850-438-1136</phone>
    </contact>
    <investigator>
      <last_name>David M Bear</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-4799</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>813-975-2897</phone>
    </contact>
    <investigator>
      <last_name>Kavita Kalidas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>StudyMetrix Research</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>636-387-5100</phone>
    </contact>
    <investigator>
      <last_name>Timothy R Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinvest Research LLC</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>413-883-7889</phone>
    </contact>
    <investigator>
      <last_name>David Gregory True</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bio Behavioral Health</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>732-244-2299</phone>
    </contact>
    <investigator>
      <last_name>Ashok K. Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Neurology, PA</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>214-827-3610</phone>
    </contact>
    <investigator>
      <last_name>Stephen Herzog</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Health Research of Hampton Roads Inc</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>757-591-8100</phone>
    </contact>
    <investigator>
      <last_name>George H Freeman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inland Northwest Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>509-960-2818</phone>
    </contact>
    <investigator>
      <last_name>Jason Aldred</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/38zkqC4LlLrl0pZt76qXvr?conditionId=6DR9WOZXRmE4e4Q2AIuqKu</url>
    <description>A Study of LY3451838 in Participants With Migraine</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 3, 2020</study_first_submitted>
  <study_first_submitted_qc>August 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2020</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>http://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

